Advertisement

Gender Differences in Atrial Fibrillation: Incidence, Mechanistic Basis of the Differences and Treatment Options

  • Naga Venkata K. C. Pothineni
  • Srikanth Vallurupalli
Chapter

Abstract

Atrial fibrillation (AF) is a common arrhythmia affecting more than 33 million people worldwide [1]. Atrial fibrillation occurs when atrial electrical remodeling (pulmonary vein triggers, multiple wavelets or rotors) initiates abnormal atrial impulses, these impulses become sustained in the face of atrial remodeling (atrial fibrosis due to factors such as hypertension, coronary artery disease, heart failure, mitral valve disease and obstructive sleep apnea) [2]. Its prevalence continues to increase, reflecting an aging population as well as an increase in risk factors known to cause AF. A wealth of evidence has improved our ability to diagnose and effectively treat AF. An intriguing aspect of this common disease - gender based differences is well recognized but poorly understood. We will explore the accumulating evidence suggests that significant differences exist in incidence, pathogenesis and response to treatment between men and women in this chapter.

Keywords

Gender Atrial fibrillation Outcomes Ischemic stroke 

Notes

Disclosures

None.

References

  1. 1.
    Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124(20):2264–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Vallurupalli S, Paydak H. Gender differences in cardiac arrhythmias in the elderly. Curr Cardiovasc Risk Rep. 2013;7:485–9.CrossRefGoogle Scholar
  4. 4.
    Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. Am Heart J. 2000;140(4):678–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Liu S, Yuan S, Kongstad O, Bertil Olsson S. Gender differences in the electrophysiological characteristics of atrioventricular conduction system and their clinical implications. Scand Cardiovasc J. 2001;35(5):313–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Tse HF, Oral H, Pelosi F, Knight BP, Strickberger S, Morady F. Effect of gender on atrial electrophysiologic changes induced by rapid atrial pacing and elevation of atrial pressure. J Cardiovasc Electrophysiol. 2001;12(9):986–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ambrosi CM, Yamada KA, Nerbonne JM, Efimov IR. Gender differences in electrophysiological gene expression in failing and non-failing human hearts. PLoS One. 2013;8(1):e54635.  https://doi.org/10.1371/journal.pone.0054635.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pothineni NV, Shirazi LF, Mehta JL. Gender differences in autonomic control of the cardiovascular system. Curr Pharmaceut Design. 2016;22(25):3829–34.CrossRefGoogle Scholar
  9. 9.
    Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadish A. Gender differences in arrhythmias. Clin Cardiol. 2002;25(2):49–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Tsai WC, Chen YC, Lin YK, Chen SA, Chen YJ. Sex differences in the electrophysiological characteristics of pulmonary veins and left atrium and their clinical implication in atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4(4):550–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Takigawa M, Kuwahara T, Takahashi A, et al. Differences in catheter ablation of paroxysmal atrial fibrillation between males and females. Int J Cardiol. 2013;168(3):1984–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Walters TE, Teh AW, Spence S, Morton JB, Kistler PM, Kalman JM. Absence of gender-based differences in the atrial and pulmonary vein substrate: a detailed electroanatomic mapping study. J Cardiovasc Electrophysiol. 2014;25(10):1065–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Zöller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J Am Heart Assoc. 2012;2(1):e003384.  https://doi.org/10.1161/JAHA.112.003384.CrossRefPubMedGoogle Scholar
  14. 14.
    Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13(6):321–32.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ravn LS, Hofman-Bang J, Dixen U, et al. Relation of 97T polymorphism in KCNE5 to risk of atrial fibrillation. Am J Cardiol. 2005;96(3):405–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Gillis AM. Atrial fibrillation and ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes. Circulation. 2017;135(6):593–608.CrossRefPubMedGoogle Scholar
  17. 17.
    Piccini JP, Simon DN, Steinberg BA, et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. JAMA Cardiol. 2016;1(3):282–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Lip GYH, Laroche C, Boriani G, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the euro observational research programme pilot survey on atrial fibrillation. Europace. 2014;17(1):24–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Schnabel RB, Pecen L, Ojeda FM, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart. 2017;103(13):1024–30.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Scheuermeyer FX, Mackay M, Christenson J, et al. There are sex differences in the demographics and risk profiles of emergency department (ED) patients with atrial fibrillation and flutter, but no apparent differences in ED management or outcomes. Acad Emerg Med. 2015;22(9):1067–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789–94.CrossRefPubMedGoogle Scholar
  22. 22.
    Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol. 2003;41(10):1690–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36(1):122–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the euro heart survey on atrial fibrillation. J Am Coll Cardiol. 2007;49(5):572–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66(6):594–601.CrossRefPubMedGoogle Scholar
  28. 28.
    Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther. 2003;73(1):31–40.CrossRefPubMedGoogle Scholar
  29. 29.
    Rochlani YM, Shah NN, Pothineni NV, Paydak H. Utilization and predictors of electrical cardioversion in patients hospitalized for atrial fibrillation. Cardiol Res Pract. 2016;2016:8956020.  https://doi.org/10.1155/2016/8956020.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Gurevitz OT, Varadachari CJ, Ammash NM, et al. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am Heart J. 2006;152(1):155.e9–13.CrossRefGoogle Scholar
  31. 31.
    Grönberg T, Nuotio I, Nikkinen M, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace. 2013;15(10):1432–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Sairaku A, Nakano Y, Oda N, et al. Prediction of sinus node dysfunction in patients with long-standing persistent atrial fibrillation using the atrial fibrillatory cycle length. J Electrocardiol. 2012;45(2):141–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Chorin E, Hochstadt A, Viskin S, et al. Female gender as independent risk factor of torsades de pointes during acquired atrioventricular block. Heart Rhythm. 2017;14(1):90–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Essebag V, Reynolds MR, Hadjis T, et al. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med. 2007;167(15):1648–53.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    January CT, Wann LS, Alpert JS, et al. ACC/AHA task force members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.CrossRefGoogle Scholar
  38. 38.
    Bhave PD, Lu X, Girotra S, Kamel H, Vaughan Sarrazin MS. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015;12(7):1406–12.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Vallakati A, Reddy M, Sharma A, et al. Impact of gender on outcomes after atrial fibrillation ablation. Int J Cardiol. 2015;187:12–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Patel D, Mohanty P, Di Biase L, et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. Heart Rhythm. 2010;7(2):167–72.CrossRefPubMedGoogle Scholar
  41. 41.
    Forleo GB, Tondo C, De Luca L, et al. Gender-related differences in catheter ablation of atrial fibrillation. Europace. 2007;9(8):613–20.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang XD, Tan HW, Gu J, et al. Efficacy and safety of catheter ablation for long-standing persistent atrial fibrillation in women. Pacing Clin Electrophysiol. 2013;36(10):1236–44.PubMedGoogle Scholar
  43. 43.
    Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation. 2013;128(19):2104–12.CrossRefPubMedGoogle Scholar
  44. 44.
    Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998;21(2):71–8.PubMedGoogle Scholar
  45. 45.
    Winkle RA, Mead RH, Engel G, Patrawala RA. Safety of lower activated clotting times during atrial fibrillation ablation using open irrigated tip catheters and a single transseptal puncture. Am J Cardiol. 2011;107(5):704–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:e3522.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Sullivan RM, Zhang J, Zamba G, Lip GY, Olshansky B. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol. 2012;110(12):1799–802.CrossRefPubMedGoogle Scholar
  48. 48.
    Cove CL, Albert CM, Andreotti F, et al. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost. 2014;111(3):385–91.CrossRefPubMedGoogle Scholar
  49. 49.
    Li Z, Wang Z, Yin Z, et al. Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget. 2017.  https://doi.org/10.18632/oncotarget.16342.
  50. 50.
    Proietti M, Raparelli V, Basili S, Olshansky B, Lip GY. Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: the AFFIRM trial. Int J Cardiol. 2016;207:258–63.CrossRefPubMedGoogle Scholar
  51. 51.
    Cochet H, Mouries A, Nivet H, et al. Age, atrial fibrillation, and structural heart disease are the main determinants of left atrial fibrosis detected by delayed-enhanced magnetic resonance imaging in a general cardiology population. J Cardiovasc Electrophysiol. 2015;26(5):484–92.CrossRefPubMedGoogle Scholar
  52. 52.
    Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB Jr, Herrington DM. The relationship between blood pressure and C-reactive protein in the multi-ethnic study of atherosclerosis (MESA). J Am Coll Cardiol. 2005;46(10):1869–74.CrossRefPubMedGoogle Scholar
  53. 53.
    Zhang R, Zhang YY, Huang XR, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010;55(4):953–60.CrossRefPubMedGoogle Scholar
  54. 54.
    Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone. 2017;100:62–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22(6):1020–32.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Mathew JS, Sachs MC, Katz R, et al. Fibroblast growth factor-23 and incident atrial fibrillation: the multi-ethnic study of atherosclerosis (MESA) and the cardiovascular health study (CHS). Circulation. 2014;130(4):298–307.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Ossei-Gerning N, Wilson IJ, Grant PJ. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost. 1998;79(4):736–40.CrossRefPubMedGoogle Scholar
  58. 58.
    Yu HT, Lee JS, Kim TH, et al. Advanced left atrial remodeling and appendage contractile dysfunction in women than in men among the patients with atrial fibrillation: potential mechanism for stroke. J Am Heart Assoc. 2016;5(7). pii: e003361.  https://doi.org/10.1161/JAHA.116.003361.
  59. 59.
    Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, Nasco E. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10(1):39–43.CrossRefPubMedGoogle Scholar
  60. 60.
    Lang C, Seyfang L, Ferrari J, et al. Do women with atrial fibrillation experience more severe strokes? Results from the Austrian stroke unit registry. Stroke. 2017;48(3):778–80.CrossRefPubMedGoogle Scholar
  61. 61.
    Lip GY, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8(2 Suppl 1):S12–20.CrossRefPubMedGoogle Scholar
  62. 62.
    Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1(1):55–62.CrossRefPubMedGoogle Scholar
  63. 63.
    Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913–23.CrossRefPubMedGoogle Scholar
  64. 64.
    Roldán V, Cancio S, Gálvez J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective ‘real-world’ inception cohort study. Am J Med. 2015;128(11):1237–43.CrossRefPubMedGoogle Scholar
  65. 65.
    Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485–90.CrossRefPubMedGoogle Scholar
  66. 66.
    Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMedGoogle Scholar
  67. 67.
    Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ. 2016;532:h7013.  https://doi.org/10.1136/bmj.h7013.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Naga Venkata K. C. Pothineni
    • 1
  • Srikanth Vallurupalli
    • 1
    • 2
  1. 1.Division of CardiologyUniversity of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Central Arkansas Veterans Healthcare SystemLittle RockUSA

Personalised recommendations